At the end of the session participants will be able to:
- describe the mechanism of action of PD-L1 inhibitors
- identify the indications for use of PD-L1 inhibitors in lymphoma
- list PD-L1 specific toxicities
Accreditation:
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1 hour per event attended. (credits are automatically calculated).
Target Audience: Hematologists Medical Oncologists, Residents
CanMEDS: Medical Expert (the integrating roles), Scholar
Declaration of Conflict of Interest: Novartis - research funding, BMS - speaking honoraria
Covid-19 infection is associated with thromboinflammation resulting in microvascular and macrovascular venous and arterial thrombosis. Anticoagulation may reduce these thrombotic complications and prevent disease progression related to Covid infection.
MDS is the premier forum for presenting the most recent advancements in Myelodysplastic Syndromes and offers you the opportunity to learn from world-renowned hematology and oncology experts, establish strong, professional relationships with international colleagues, form collaborations and grow in your career.
The 2022 Regional Symposium will cover the latest science on basic, translational and clinical aspects of MDS diagnosis, prognosis, and treatment. The meeting will also feature abstract presentations on novel research discoveries that can greatly improve the way we see and treat patients with MDS.
Be part of the advancement of MDS science and patient care by joining the global community at MDSR 2022 on 4 - 5 November 2022 in Kyoto, Japan.
The AGM will be held to inform the membership of updates and fulfill the requirements of the by-laws of the Society.
We will review the epidemiology and clinical relevance of cancer-associated thrombosis and discuss how to tailor anticoagulation in this patient population. This webinar is offered free of charge to CHS Members.
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours.
LEARNING OBJECTIVES: After attending this activity, participants will be able to: • Evaluate new efficacy and safety data of frontline treatments for patients with advanced classical Hodgkin lymphoma (cHL) • Discuss and interpret trial results in order to better select treatment regimens for advanced cHL...
After attending this activity, participants will be able to: • Evaluate new efficacy and safety data of frontline treatments for patients with advanced classical Hodgkin lymphoma (cHL) • Discuss and interpret trial results in order to better select treatment regimens for advanced cHL in the...